The inhibitory action of the antisense oligodeoxynucleotide to the expression of vascular endothelial growth factor by radiotherapy in a prostate cancer cell line.
- Author:
Dong-Ya MENG
1
;
Wen-Cheng XUE
;
Xiao-Fang HU
;
Yi-Nan WANG
;
Jun LUO
Author Information
- Publication Type:Journal Article
- MeSH: DNA, Antisense; pharmacology; Endothelial Growth Factors; antagonists & inhibitors; blood; genetics; Gene Expression; drug effects; radiation effects; Humans; Intercellular Signaling Peptides and Proteins; blood; genetics; Lymphokines; antagonists & inhibitors; blood; genetics; Male; Prostatic Neoplasms; blood; pathology; Radiotherapy; adverse effects; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors
- From:National Journal of Andrology 2002;8(2):95-97
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVESTo investigate mechanism for the increasing level of serum vascular endothelial growth factor(VEGF) in tumour patients during radiotherapy and the inhibitory action of the antisense oligodeoxynucleotide (AS-ODN) to the expression of VEGF protein by radiotherapy in the prostate cancer cell line (PC3M).
METHODSTo observe the changes of serum VEGF in the prostate cancer patients during radiotherapy dynamically and the inhibitory action of the antisense oligodeoxynucleotide to the expression of VEGF by radiotherapy in PC3M.
RESULTSThe changes of serum VEGF in three patients receiving radiotherapy had been observed continuously. The levels of serum VEGF began to increase when the patients received radiotherapy and rised up to peak value after fifteen days, then declined to the range of pre-radiotherapy. Irradiating the PC3M cells with X-rays significantly increased the VEGF expression and secretion. The expression of VEGF protein in the group treated by VEGF AS-ODNs and X-ray irradiation decreased significantly than the group treated only by X-ray irradiation.
CONCLUSIONSThe induction of VEGF protein expression by X-ray irradiation in tumor cells may result in the increasing of the VEGF in the prostate cancer patients during radiotherapy and the induction can be blocked by VEGF AS-ODNs.
